Aoyagi Satoru, Akiyama Masashi, Shimizu Hiroshi
Department of Dermatology, Hokkaido University Graduate School of Medicine, N15 W7 Kita-ku, Sapporo, Hokkaido 060-8638, Japan.
J Dermatol Sci. 2008 Jun;50(3):177-84. doi: 10.1016/j.jdermsci.2007.12.002. Epub 2008 Jan 14.
Invasive extramammary Paget's disease (EMPD) is commonly associated with a poor prognosis. Although early detection of micro invasion can improve the prognosis, diagnosis is not always straightforward in some EMPD cases. Several clinical studies have proposed mechanisms underlying the increased invasiveness of EMPD; however, molecular markers indicative of the invasiveness have yet to be well characterized.
The purpose of this study was to identify a reliable immunohistochemical marker for predicting the risk of invasion and metastasis in EMPD cases.
A total of 32 specimens from 23 primary EMPD cases were analyzed by immunohistochemical staining. In formalin-fixed, paraffin-embedded tissue sections, immunolabeling of tumor cells were scored by stain intensity on a four-tiered scale. Using antibodies against several tumor proliferation markers, such as Her2, p53, Ki-67, cyclin D1 and Bcl-2, we determined the correlation between the expression of these molecular markers and the types of EMPD lesions (in situ, invasive or metastatic).
In contrast to Her2, p53 and Bcl-2, which are similarly expressed among different types of lesions, Ki-67 and cyclin D1 are expressed at significantly higher levels in invasive lesions than in situ lesions (P<0.01 and P<0.05, respectively). Furthermore, the mean of the sum of Ki-67 and cyclin D1 expression scores was significantly higher in invasive lesions, compared to the scores obtained for in situ lesions. In addition, the difference was more significant (P<or=0.001) than each of these independent marker.
Combined high expression of Ki-67 and cyclin D1 was highly associated with invasive lesions of EMPD.
侵袭性乳腺外佩吉特病(EMPD)通常预后较差。虽然早期检测微侵袭可改善预后,但在某些EMPD病例中诊断并不总是简单直接。多项临床研究提出了EMPD侵袭性增加的潜在机制;然而,指示侵袭性的分子标志物尚未得到很好的表征。
本研究的目的是确定一种可靠的免疫组化标志物,用于预测EMPD病例的侵袭和转移风险。
通过免疫组化染色分析了来自23例原发性EMPD病例的32个标本。在福尔马林固定、石蜡包埋的组织切片中,根据染色强度在四级量表上对肿瘤细胞的免疫标记进行评分。使用针对几种肿瘤增殖标志物的抗体,如Her2、p53、Ki-67、细胞周期蛋白D1和Bcl-2,我们确定了这些分子标志物的表达与EMPD病变类型(原位、侵袭性或转移性)之间的相关性。
与在不同类型病变中表达相似的Her2、p53和Bcl-2不同,Ki-67和细胞周期蛋白D1在侵袭性病变中的表达水平明显高于原位病变(分别为P<0.01和P<0.05)。此外,与原位病变获得的评分相比,侵袭性病变中Ki-67和细胞周期蛋白D1表达评分总和的平均值明显更高。此外,这种差异比这些独立标志物中的每一个都更显著(P≤0.001)。
Ki-67和细胞周期蛋白D1的联合高表达与EMPD的侵袭性病变高度相关。